The results are derived from a substudy of the STABILITY trial [13, 14], which evaluated the effects of the lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor darapladib versus placebo in patients with CAD. This evidence concerns the gene PLA2G7 and coronary artery disorder.